日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

From fracture to function: return-to-sport after acetabular fractures

从骨折到功能恢复:髋臼骨折后的重返运动

Schiltenwolf, Anna L; Histing, Tina; Laux, Florian; Kueper, Markus A; Doebele, Stefan; Herath, Steven C

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

米拉德美坦治疗MDM2扩增和TP53野生型晚期实体瘤:临床前和II期临床试验结果

Dumbrava, Ecaterina E; Stinchcombe, Thomas E; Gounder, Mrinal; Cote, Gregory M; Hanna, Glenn J; Sumrall, Bradley; Wise-Draper, Trisha M; Kanaan, Mohammed; Duffy, Steven; Sumey, Christopher; Cobb, Patrick; Forbes, Andre; Beckmann, Aviva G; Schadt, Eric E; Ku, Nora; Tirunagaru, Vijaya G; Singh, Kanchan; Pei, Xinyu; Xu, Feng; Doebele, Robert C; Chen, Christopher T

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.

癌症相关成纤维细胞通过同时激活整合素和MET信号通路,使EML4-ALK驱动的肺癌对ALK抑制剂产生耐药性。

Hu Qianqian, Remsing Rix Lily L, Desai Bina, Miroshnychenko Daria, Li Xueli, Welsh Eric A, Fang Bin, Wright Gabriela M, Chaudhary Neelkamal, Kroeger Jodi L, Doebele Robert C, Koomen John M, Haura Eric B, Marusyk Andriy, Rix Uwe

Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

GATA3突变转移性激素受体阳性乳腺癌的基因组和蛋白质组分析及其对临床结果的影响

Medford, Arielle J; Velimirovic, Marko; Gefen, Yifat; Niemierko, Andrzej; Gerratana, Lorenzo; Davis, Andrew A; Clifton, Katherine; Keenan, Jennifer; Podany, Emily; Hensing, Whitney L; Reduzzi, Carolina; Dai, Charles S; Kiedrowski, Lesli A; Spring, Laura M; Ellisen, Leif W; Doebele, Robert C; Cristofanilli, Massimo; Getz, Gad; Bardia, Aditya

Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy

布鲁顿酪氨酸激酶抑制剂对侵袭性淋巴瘤的疗效与慢性选择性自噬有关

James D Phelan ,Sebastian Scheich ,Jaewoo Choi ,George W Wright ,Björn Häupl ,Ryan M Young ,Sara A Rieke ,Martine Pape ,Yanlong Ji ,Henning Urlaub ,Arnold Bolomsky ,Carmen Doebele ,Alena Zindel ,Tanja Wotapek ,Monica Kasbekar ,Brett Collinge ,Da Wei Huang ,Zana A Coulibaly ,Vivian M Morris ,Xiaoxuan Zhuang ,Julius C Enssle ,Xin Yu ,Weihong Xu ,Yandan Yang ,Hong Zhao ,Zhuo Wang ,Andy D Tran ,Christopher J Shoemaker ,Galina Shevchenko ,Daniel J Hodson ,Arthur L Shaffer 3rd ,Louis M Staudt ,Thomas Oellerich

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

新辅助奥希替尼治疗I-IIIA期表皮生长因子受体突变型非小细胞肺癌:一项II期多中心研究

Blakely, Collin M; Urisman, Anatoly; Gubens, Matthew A; Mulvey, Claire K; Allen, Greg M; Shiboski, Stephen C; Rotow, Julia K; Chakrabarti, Turja; Kerr, D Lucas; Aredo, Jacqueline V; Bacaltos, Bianca; Gee, Megan; Tan, Lisa; Jones, Kirk D; Devine, W Patrick; Doebele, Robert C; Aisner, Dara L; Patil, Tejas; Schenk, Erin L; Bivona, Trever G; Riess, Jonathan W; Coleman, Melissa; Kratz, Johannes R; Jablons, David M

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

致癌 EML4-ALK 组装体抑制生长因子感知并调节药物耐受性

David Gonzalez-Martinez #, Lee Roth #, Thomas R Mumford, Juan Guan, Anh Le, Robert C Doebele, Bo Huang, Asmin Tulpule, Magdalena Niewiadomska-Bugaj, Trever G Bivona, Lukasz J Bugaj3

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2

ROS1 抑制剂的差异网络分析揭示了劳拉替尼通过共同靶向 PYK2 发挥多药理作用

Yi Liao, Lily L Remsing Rix, Xueli Li, Bin Fang, Victoria Izumi, Eric A Welsh, Andrii Monastyrskyi, Eric B Haura, John M Koomen, Robert C Doebele, Uwe Rix

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

MIG6 通过 EGFR 旁路信号传导介导对 ALK/ROS1 融合激酶抑制的适应性和获得性抗性

Nan Chen, Logan C Tyler, Anh T Le, Eric A Welsh, Bin Fang, Andrew Elliott, Kurtis D Davies, Thomas Danhorn, Gregory J Riely, Marc Ladanyi, Eric B Haura, Robert C Doebele

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Milademetan(一种 MDM2 抑制剂)在晚期脂肪肉瘤、实体瘤或淋巴瘤患者中的首次人体 I 期研究

Gounder, Mrinal M; Bauer, Todd M; Schwartz, Gary K; Weise, Amy M; LoRusso, Patricia; Kumar, Prasanna; Tao, Ben; Hong, Ying; Patel, Parul; Lu, Yasong; Lesegretain, Arnaud; Tirunagaru, Vijaya G; Xu, Feng; Doebele, Robert C; Hong, David S